Related Experiment Video

Updated: Jul 14, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

[Regenerative therapy in patients with a revascularized acute anterior myocardial infarction and depressed

José Suárez de Lezo1, Concepción Herrera, Manuel Pan

  • 1Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain. grupo_corpal@arrakis.es

Revista Espanola De Cardiologia
|May 25, 2007
PubMed

Insights

Intracoronary bone marrow cell infusion improved ejection fraction in acute myocardial infarction patients. Granulocyte colony-stimulating factor (G-CSF) did not significantly enhance functional recovery in this study.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Stem Cell Therapy

Background:

  • Acute myocardial infarction (AMI) often leads to impaired left ventricular function.
  • Distinguishing the effects of early revascularization and regenerative therapies on cardiac function is challenging.
  • Patients with anterior wall AMI and ejection fraction < 45% represent a group with significant ventricular dysfunction.

Purpose of the Study:

  • To compare the effects of intracoronary autologous mononuclear bone marrow cells versus systemic granulocyte colony-stimulating factor (G-CSF) on left ventricular function in patients with anterior wall AMI.
  • To evaluate the efficacy of regenerative therapy in improving ejection fraction post-AMI.
  • To assess the impact of stem cell mobilization via G-CSF on cardiac recovery.

Main Methods:

  • Randomized controlled trial involving three groups: intracoronary bone marrow cells (Group I), systemic G-CSF (Group II), and control (Group III).
  • Intracoronary infusion of bone marrow cells occurred 7 days post-AMI.
  • G-CSF was administered subcutaneously for 10 days starting 5 days post-AMI.
  • Left ventricular ejection fraction was assessed at baseline and 3-month follow-up.

Main Results:

  • Group I (bone marrow cells) showed a 20% increase in mean ejection fraction.
  • Group II (G-CSF) demonstrated a 4% increase, and Group III (control) showed a 6% increase.
  • The improvement in ejection fraction in Group I was statistically significant compared to Groups II and III.

Conclusions:

  • Intracoronary infusion of autologous mononuclear bone marrow cells is associated with improved short-term left ventricular functional recovery in AMI patients.
  • Systemic administration of G-CSF for stem cell mobilization did not yield significant functional recovery benefits in this patient cohort.
  • Regenerative therapy with bone marrow cells shows promise for enhancing cardiac function after myocardial infarction.
Abstract

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...